We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Short Synthetic Probes Utilized for Bladder Cancer Diagnosis

By LabMedica International staff writers
Posted on 08 Jul 2010
A novel assay has been developed to test for multiple tumor markers in bladder cancer.

Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) can be used to screen multiple target sequences simultaneously in a single reaction, allowing for rapid early screening of tumor markers.

Commercially available MS-MLPA kits are not available for many diseases, and custom probe design has been limited by problems of chemically synthesizing longer nucleotides. More...
Dr. Per Guldberg of the Danish Cancer Society (Copenhagen, Denmark) and colleagues from the Herlev University Hospital (Copenhagen, Denmark) have modified this assay by using multiple short synthetic probes to test for tumor markers in bladder cancer. They found that paired tumor and urine samples in most cases showed identical marker patterns, suggesting that this assay may be used for noninvasive diagnosis and disease monitoring.

The study was published in the July 2010 edition of the Journal of Molecular Diagnostics. The authors suggested, "The use of multiple short synthetic probes may provide a simple and cost-effective approach to custom-designed MLPA." In future studies, Dr. Guldberg's group will examine how "the same approach may be used for most other MLPA applications and thus provide the basis for a more widespread usage of the MLPA technology."

Related Links:
Danish Cancer Society
Herlev University Hospital



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.